IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
25.61
+0.82 (3.31%)
Dec 20, 2024, 4:00 PM EST - Market closed
IDEAYA Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Revenue | 3.92 | 23.39 | 50.93 | 27.94 | 19.54 | - | Upgrade
|
| Revenue Growth (YoY) | -83.30% | -54.08% | 82.28% | 43.01% | - | - | Upgrade
|
| Cost of Revenue | 193.26 | 129.51 | 89.54 | 58.16 | 39.7 | 34.32 | Upgrade
|
| Gross Profit | -189.34 | -106.12 | -38.61 | -30.22 | -20.16 | -34.32 | Upgrade
|
| Selling, General & Admin | 35.42 | 28.31 | 23.9 | 20.05 | 15.18 | 9.95 | Upgrade
|
| Operating Expenses | 35.42 | 28.31 | 23.9 | 20.05 | 15.18 | 9.95 | Upgrade
|
| Operating Income | -224.75 | -134.43 | -62.5 | -50.27 | -35.34 | -44.27 | Upgrade
|
| Interest & Investment Income | 46.63 | 21.47 | 3.85 | 0.51 | 0.83 | 2.29 | Upgrade
|
| EBT Excluding Unusual Items | -178.12 | -112.96 | -58.66 | -49.76 | -34.51 | -41.98 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.02 | 0.01 | Upgrade
|
| Pretax Income | -178.12 | -112.96 | -58.66 | -49.76 | -34.5 | -41.98 | Upgrade
|
| Net Income | -178.12 | -112.96 | -58.66 | -49.76 | -34.5 | -41.98 | Upgrade
|
| Net Income to Common | -178.12 | -112.96 | -58.66 | -49.76 | -34.5 | -41.98 | Upgrade
|
| Shares Outstanding (Basic) | 76 | 58 | 41 | 35 | 25 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 76 | 58 | 41 | 35 | 25 | 12 | Upgrade
|
| Shares Change (YoY) | 43.06% | 38.79% | 17.57% | 42.60% | 97.82% | 1206.87% | Upgrade
|
| EPS (Basic) | -2.34 | -1.96 | -1.42 | -1.41 | -1.40 | -3.36 | Upgrade
|
| EPS (Diluted) | -2.34 | -1.96 | -1.42 | -1.41 | -1.40 | -3.36 | Upgrade
|
| Free Cash Flow | -153.27 | -117.59 | -90.62 | -58.42 | 54.97 | -40.67 | Upgrade
|
| Free Cash Flow Per Share | -2.01 | -2.04 | -2.19 | -1.66 | 2.22 | -3.25 | Upgrade
|
| Gross Margin | - | - | -75.80% | -108.15% | -103.18% | - | Upgrade
|
| Operating Margin | -5730.60% | -574.85% | -122.72% | -179.91% | -180.90% | - | Upgrade
|
| Profit Margin | -4541.56% | -483.05% | -115.17% | -178.10% | -176.55% | - | Upgrade
|
| Free Cash Flow Margin | -3907.96% | -502.85% | -177.92% | -209.09% | 281.35% | - | Upgrade
|
| EBITDA | -222.31 | -131.95 | -60.4 | -48.54 | -33.96 | -43.03 | Upgrade
|
| EBITDA Margin | - | - | -118.59% | -173.73% | -173.83% | - | Upgrade
|
| D&A For EBITDA | 2.44 | 2.48 | 2.1 | 1.73 | 1.38 | 1.25 | Upgrade
|
| EBIT | -224.75 | -134.43 | -62.5 | -50.27 | -35.34 | -44.27 | Upgrade
|
| EBIT Margin | - | - | -122.72% | -179.91% | -180.90% | - | Upgrade
|
| Revenue as Reported | 3.92 | 23.39 | 50.93 | 27.94 | 19.54 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.